Welcome to our dedicated page for Atai Beckley news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on Atai Beckley stock.
AtaiBeckley Inc. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical and biotechnology company focused on developing effective, rapid-acting and convenient mental health treatments. The AtaiBeckley news feed on Stock Titan aggregates company announcements, press releases and regulatory disclosures so readers can follow how its clinical programs and corporate developments evolve over time.
News about AtaiBeckley frequently highlights progress across its pipeline of investigational therapies. This includes updates on BPL-003, a mebufotenin (5-MeO-DMT) benzoate nasal spray for treatment-resistant depression and alcohol use disorder; VLS-01, a DMT buccal film for treatment-resistant depression; and EMP-01, an oral R-MDMA formulation for social anxiety disorder. Company releases have covered Phase 2b and open-label extension data for BPL-003, enrollment and site expansion for VLS-01 trials, and exploratory Phase 2a work for EMP-01, as well as regulatory milestones such as FDA Breakthrough Therapy designation for BPL-003.
Investors and observers can also use the ATAI news page to follow corporate events, including the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited to form AtaiBeckley, the company’s redomiciliation to the United States as AtaiBeckley Inc., and its addition to the Nasdaq Biotechnology Index. Filings and press releases related to public offerings, grants from organizations such as the National Institute on Drug Abuse, and intellectual property developments like the U.S. patent granted for EMP-01 are also reflected in the news flow.
By reviewing AtaiBeckley news in one place, readers can track key clinical milestones, financing activities, regulatory designations and strategic transactions that shape the company’s efforts in mental health therapeutics. The ATAI news page can be revisited regularly to see new company communications and related market updates as they are released.
atai Life Sciences (NASDAQ: ATAI) has announced the pricing of a registered underwritten public offering of 26,190,477 common shares at $2.10 per share. The company expects to raise approximately $55 million in gross proceeds before deducting underwriting costs and other expenses.
The offering includes a 30-day option for the underwriter to purchase up to an additional 3,928,571 common shares. Berenberg is serving as the sole bookrunner for the offering, which is expected to close on February 14, 2025. The proceeds will be used for general corporate purposes, including working capital and advancing clinical development of product candidates and programs.
The offering is being made through an effective shelf registration statement filed with the SEC on July 1, 2022, and declared effective on July 11, 2022.
atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health disorder treatments, has announced a proposed registered underwritten public offering of $55 million in common shares. The company will grant underwriters a 30-day option to purchase up to an additional $8.25 million of common shares.
Berenberg is serving as the sole bookrunner for the offering. The proceeds will be used for general corporate purposes, including working capital and advancing clinical development of product candidates and programs. The offering is being made through an effective shelf registration statement filed with the SEC on July 1, 2022.
atai Life Sciences (NASDAQ: ATAI) announced positive topline results from Beckley Psytech's Phase 2a open-label study of BPL-003, a synthetic intranasal formulation of 5-MeO-DMT benzoate, in treating alcohol use disorder (AUD). The study, involving 12 patients with moderate to severe AUD, demonstrated significant improvements following a single dose combined with relapse prevention therapy:
Key results after 12 weeks include:
- Reduction in daily alcohol consumption from 9.3 to 2.2 units
- Decrease in heavy drinking days from 56% to 13%
- Increase in abstinent days from 33% to 81%
- 50% of patients maintained complete abstinence
The treatment was well-tolerated with only mild to moderate adverse events reported, and patients were typically ready for discharge within two hours. Beckley Psytech plans to evaluate future development options and share additional clinical data throughout 2025.
atai Life Sciences (NASDAQ: ATAI) has announced significant leadership changes to advance its pipeline of mental health therapeutics. Srinivas Rao, M.D., Ph.D., has become the sole Chief Executive Officer, while Kevin Craig, M.D. has been promoted to Chief Medical Officer, Glenn Short, Ph.D. to Chief Scientific Officer, and Gerd Kochendoerfer, Ph.D. has joined as Chief Operating Officer.
The company is at a important phase with VLS-01 and EMP-01 advancing into Phase 2 clinical trials. VLS-01 is currently screening patients, and the company anticipates mid-year Phase 2b data readout for Beckley Psytech's BPL-003, marking a significant step toward developing commercially scalable short-duration psychedelic therapies for treatment-resistant depression.
Each new leader brings substantial expertise: Dr. Craig has over 20 years of clinical experience, Dr. Short possesses more than 20 years of industry experience, and Dr. Kochendoerfer contributes 25+ years of pharmaceutical and biotech leadership experience.
atai Life Sciences (NASDAQ: ATAI) reported Q3 2024 financial results and pipeline updates. The FDA cleared the IND for VLS-01 (buccal film DMT) for treatment-resistant depression, with Phase 2 study initiation expected around YE'24. The company plans to initiate Phase 2 study of EMP-01 (oral R-MDMA) for social anxiety disorder around YE'24. Q3 net loss was $26.3M, with cash position at $101.0M. R&D expenses were $12.4M, down from $13.3M year-over-year, while G&A expenses decreased to $10.3M from $13.6M. The company expects current funding to support operations into 2026.
atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on transforming mental health disorder treatments, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event is scheduled from October 15 – 17, 2024.
Key details of atai's involvement include:
- Participant: Srinivas Rao, M.D., Ph.D., Co-founder and Co-CEO
- Format: Virtual fireside chat
- Date: Wednesday, October 16, 2024
- Presentation Time: 3:30 P.M. EDT
A webcast registration link is provided, and an archived replay will be available on the Investors section of atai's website under Events for up to 30 days after the presentation.
atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health disorders, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. The company's management team will engage in a fireside chat on Tuesday, September 10 at 4:30 P.M. EDT, along with 1x1 investor meetings.
Investors can access the fireside chat via a provided webcast link, and an archived replay will be available on the company's website for up to 90 days. This participation offers atai an opportunity to showcase its progress and strategies in transforming mental health treatment to a global investment audience.
atai Life Sciences (NASDAQ: ATAI) reported Q2 2024 financial results and corporate updates. Key highlights:
- Positive Phase 1b results for VLS-01 (buccal film DMT) in treatment-resistant depression
- Plans to initiate Phase 2 studies for VLS-01 and EMP-01 (oral R-MDMA) around year-end 2024
- Cash and securities of $103.3 million as of June 30, 2024
- Funding expected to last into 2026
- R&D expenses decreased to $12.6 million from $15.5 million year-over-year
- G&A expenses decreased to $13.4 million from $16.6 million year-over-year
- Net loss of $57.3 million, up from $33.0 million in Q2 2023
atai Life Sciences (NASDAQ: ATAI) announced positive preliminary results from its Phase 1b trial of VLS-01, a proprietary oral transmucosal film formulation of N,N-dimethyltryptamine (DMT). The trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of VLS-01 compared to intravenous DMT in healthy participants.
Key findings include:
- Dose-proportional peak plasma concentrations achieved within 30-45 minutes
- Robust subjective effects at 120mg and 160mg doses
- Favorable safety profile with mild to moderate adverse events
- Short psychedelic experience resolving within 90-120 minutes
Based on these results, atai plans to initiate a Phase 2 study in patients with treatment-resistant depression around year-end 2024, with topline data expected around year-end 2025.
atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health disorder treatments, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event will take place in Boston, MA from August 13-15, 2024.
Key details of atai's involvement include:
- A fireside chat scheduled for Wednesday, August 14 at 11:00 A.M. EDT
- One-on-one investor meetings
- A webcast link provided for remote access
An archived replay of the fireside chat will be available on the Investors section of atai's website under Events for up to 90 days following the conference.